Sanofi hands back rights to Oxford Biomedica gene therapies
admin 9th June 2020 Uncategorised 0The move follows a portfolio review by the French drug giant More: Sanofi hands back rights to Oxford Biomedica gene therapies Source: News
read more
The move follows a portfolio review by the French drug giant More: Sanofi hands back rights to Oxford Biomedica gene therapies Source: News
read moreThe new condition is called Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2 (PIMS-TS) More: Kawasaki-like syndrome linked to coronavirus is new condition Source: News
read moreIt is not certain how much more clinical benefit Sarclisa has over existing therapies, the Institute said More: NICE rejects Sanofi's Sarclisa in preliminary guidelines Source: News
read moreThe research also suggests that coronavirus was more infectious than previously estimated More: EU lockdowns saved more than 3m lives, research indicates Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals